IPP Bureau

Sartorius and Nanotein Technologies partner to advance cell therapy manufacturing
Sartorius and Nanotein Technologies partner to advance cell therapy manufacturing

By IPP Bureau - August 12, 2025

Under an exclusive distribution agreement, Sartorius Stedim Biotech will offer Nanotein’s lead products globally

Asian Institute of Nephrology & Urology expands hospital in Banjara Hills, Hyderabad
Asian Institute of Nephrology & Urology expands hospital in Banjara Hills, Hyderabad

By IPP Bureau - August 12, 2025

AINU is set to accelerate its expansion footprint, enhance operational capabilities

Sandoz launches renewable energy partnership
Sandoz launches renewable energy partnership

By IPP Bureau - August 12, 2025

The agreement complements other PPAs for Sandoz production sites globally

Boehringer’s lung cancer medicine gets FDA approval
Boehringer’s lung cancer medicine gets FDA approval

By IPP Bureau - August 12, 2025

FDA grants accelerated approval to zongertinib for HER2 TKD-Mutated Non-Squamous NSCLC

Gland Pharma gets approval for Norepinephrine Bitartrate in 5% Dextrose injection bags
Gland Pharma gets approval for Norepinephrine Bitartrate in 5% Dextrose injection bags

By IPP Bureau - August 12, 2025

The Product is bioequivalent and therapeutically equivalent to the reference listed drug (RLD), Norepinephrine Bitartratein 5% Dextrose of Baxter Healthcare Corp

Lupin partners with Sadoz to commercialise Ranibizumab biosimilar
Lupin partners with Sadoz to commercialise Ranibizumab biosimilar

By IPP Bureau - August 12, 2025

Ranibizumab is a recombinant humanized IgG1 monoclonal antibody fragment that binds to and inhibits vascular endothelial growth factor A

Gland Pharma receives FDA approval for Cangrelor for Injection 50 mg/vial
Gland Pharma receives FDA approval for Cangrelor for Injection 50 mg/vial

By IPP Bureau - August 12, 2025

The product is bioequivalent and therapeutically equivalent to the reference listed drug (RLD), KENGREAL of Chiesi USA

Cohance to invest $10 million to expand cGMP bioconjugation capabilities in US
Cohance to invest $10 million to expand cGMP bioconjugation capabilities in US

By IPP Bureau - August 12, 2025

NJ Bio is currently executing a major new program for an existing innovator customer with multiple ADC candidates in their pipeline

Cohance to invest Rs. 23 crore on cGMP Oligonucleotide facility at Hyderabad
Cohance to invest Rs. 23 crore on cGMP Oligonucleotide facility at Hyderabad

By IPP Bureau - August 12, 2025

This strategic investment strengthens Cohance's integrated oligonucleotide platform

Dr. Jitendra Singh inaugurates animal stem cell BioBank and laboratory at NIAB, Hyderabad
Dr. Jitendra Singh inaugurates animal stem cell BioBank and laboratory at NIAB, Hyderabad

By IPP Bureau - August 11, 2025

Minister releases five breakthrough veterinary technologies to strengthen diagnostics and combat antimicrobial resistance

Lupin launches Glucagon for Injection USP, 1mg/Vial in US
Lupin launches Glucagon for Injection USP, 1mg/Vial in US

By IPP Bureau - August 11, 2025

Glucagon is indicated for the treatment of severe hypoglycemia in pediatric and adult patients with diabetes mellitus

Zydus receives final approval from USFDA for Diltiazem Hydrochloride Tablets USP
Zydus receives final approval from USFDA for Diltiazem Hydrochloride Tablets USP

By IPP Bureau - August 11, 2025

Diltiazem works by relaxing blood vessels, which reduces the workload on the heart and increases blood and oxygen supply to the heart muscle

Shilpa Medicare receives approval of NorUDCA tablets for treatment of NAFLD in India
Shilpa Medicare receives approval of NorUDCA tablets for treatment of NAFLD in India

By IPP Bureau - August 11, 2025

NorUDCA is the first?in?class treatment for Non?alcoholic Fatty Liver Disease (NAFLD) in India

SMS Pharmaceuticals reports consolidated Q1 FY26 at Rs. 20.49 Cr
SMS Pharmaceuticals reports consolidated Q1 FY26 at Rs. 20.49 Cr

By IPP Bureau - August 11, 2025

SMS Pharmaceuticals has reported total income of Rs. 196.64 crores during the period ended June 30, 2025

LAXAI Life Sciences appoints Sripathy Venkatraman as CEO
LAXAI Life Sciences appoints Sripathy Venkatraman as CEO

By IPP Bureau - August 11, 2025

Dr. Venkatraman brings over 25 years of experience in small molecule and Biologics drug development, manufacturing, and advancing strategic growth initiatives

Latest Stories

Interviews

Packaging